July 23 (Reuters) - Biopharmaceutical firm Telix Pharmaceuticals (TLX) said on Monday it has launched an offering of A$600 million ($397.5 million) of convertible notes due 2029, in a bid to fund key clinical development programs across its theranostics portfolio.
($1 = 1.5094 Australian dollars)
- Forums
- ASX - By Stock
- TLX
- News: TLX Australia's Telix Pharmaceuticals launches $397.5 mln convertible bonds offering
News: TLX Australia's Telix Pharmaceuticals launches $397.5 mln convertible bonds offering
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.23 |
Change
-0.160(0.78%) |
Mkt cap ! $6.824B |
Open | High | Low | Value | Volume |
$20.63 | $20.72 | $20.10 | $3.031M | 148.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 697 | $20.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.23 | 1522 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 1881 | 20.220 |
7 | 806 | 20.210 |
9 | 671 | 20.200 |
7 | 712 | 20.190 |
6 | 627 | 20.180 |
Price($) | Vol. | No. |
---|---|---|
20.240 | 176 | 2 |
20.250 | 466 | 4 |
20.260 | 769 | 6 |
20.270 | 671 | 4 |
20.280 | 597 | 6 |
Last trade - 12.08pm 03/10/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |